title: [Clinical outcomes of nephron sparing surgery for T1 renal cell carcinoma].
abstract: OBJECTIVE
  To investigate the safety and effect of nephron-sparing surgery (NSS) in treatment of T1a and T1b renal cell carcinoma.
  
  
  METHODS
  Retrospective analyzed the clinical data of 101 patients with T1 renal cell carcinoma underwent NSS from November 1999 to December 2009.Including 79 male and 22 female with the mean age of 52.3 years (ranged 28 to 79 years). Based on tumor pathologic diameter, 101 patients were divided into T1a group with 62 patient and T1b group with 39 cases. Demographic, intraoperative, postoperative and follow-up data were compared between the 2 groups.
  
  
  RESULTS
  The operation were performed successfully in all the 101 cases. The mean operation time was (151 ± 80) min in group T1a and (158 ± 50) min in group T1b with no statistical difference (P = 0.32). The mean blood loss was (322 ± 596) ml in group T1a and (308 ± 239) ml in group T1b (P = 0.45). Postoperative follow-up ranged from 8 to 102 months with a mean of 38.4 months. One patient in T1b group died of distant metastasis 36 months after operation. Others were no tumor recurred.
  
  
  CONCLUSIONS
  Nephron-sparing surgery is safe and effective for the treatment of T1a and T1b renal cell carcinoma.
authors.affiliation: Department of Urology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong 510060, China.
authors.forename: Pei
authors.initials: P
authors.lastname: Dong
authors.forename: Zhi-Ling
authors.initials: ZL
authors.lastname: Zhang
authors.forename: Guo-Liang
authors.initials: GL
authors.lastname: Hou
authors.forename: Kai
authors.initials: K
authors.lastname: Yao
authors.forename: Zhuo-Wei
authors.initials: ZW
authors.lastname: Liu
authors.forename: Hui
authors.initials: H
authors.lastname: Han
authors.forename: Zi-Ke
authors.initials: ZK
authors.lastname: Qin
authors.forename: Fang-Jian
authors.initials: FJ
authors.lastname: Zhou
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome